As a cytochrome P450 17A1 (CYP17A1) inhibitor, abiraterone impedes the production of androgens in adrenal glands, cancer cells and other sources [15], whilst enzalutamide directly binds to the AR and blocks nuclear translocation and activation of downstream AR-related pathways [16]. This evidence concerns the gene CYP17A1 and cancer.